Amgen (Nasdaq: AMGN) announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa(R) (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases...
More...